<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03765476</url>
  </required_header>
  <id_info>
    <org_study_id>SALIENCE</org_study_id>
    <nct_id>NCT03765476</nct_id>
  </id_info>
  <brief_title>Validation of a Training Program for Patients With Alcohol Use Disorder</brief_title>
  <official_title>Validation of a Computer-based Training Program for Patients With Alcohol Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Institute of Mental Health, Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Institute of Mental Health, Mannheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to detect how the Web-based program SALIENCE affects patients with&#xD;
      alcohol-use Disorder in terms of craving, cognitive functions and risk of relapse.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the web-based program SALIENCE (&quot;Stop Alcohol In Everyday life - New Choices and&#xD;
      Evaluations&quot;) the patient has to make decisions for non-alcoholic and against alcoholic&#xD;
      drinks. Therefore there are several scenarios, which are supposed to let the patient&#xD;
      integrate these choices into a realistic, everyday life, setting and help the patient to&#xD;
      maintain abstinence in upcoming &quot;high risk situations&quot;. It has been developed as an add-on&#xD;
      therapy to increase the overall outcome.&#xD;
&#xD;
      Participating patients with alcohol-use disorder are to receive an initial screening&#xD;
      including questionnaires and neuropsychological tests. Then the patients receive three&#xD;
      training sessions with SALIENCE each week.&#xD;
&#xD;
      After three weeks there is another examination. After these three weeks, there is a 90 day&#xD;
      period in which there are online follow-ups every two weeks to assess the craving and relapse&#xD;
      of the participants. After the 90 day period there is a third examination analog to the first&#xD;
      and the second one.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>one group receives add-on- intervention &quot;SALIENCE&quot;</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in alcohol craving</measure>
    <time_frame>directly before and after each SALIENCE session (3 SALIENCE sessions per week over 3 weeks)</time_frame>
    <description>Visual Analogue Scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in attentional bias</measure>
    <time_frame>directly before and after each SALIENCE session (3 SALIENCE sessions per week over 3 weeks)</time_frame>
    <description>Dotprobe-Task (MacLeod, Mathews, &amp; Tata, 1986)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in alcohol interference</measure>
    <time_frame>directly before and after each SALIENCE session (3 SALIENCE sessions per week over 3 weeks)</time_frame>
    <description>Alcohol Stroop Test (Brand, Leichsenring-Driessen, Beblo, Kremer, &amp; Driessen, 2009)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in approach-avoidance tendencies</measure>
    <time_frame>directly before and after each SALIENCE session (3 SALIENCE sessions per week over 3 weeks)</time_frame>
    <description>Approach Avoidance Task (AAT) (R. W. Wiers et al., 2009)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>90 days after study inclusion</time_frame>
    <description>time to first severe relapse</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Alcohol Use Disorder</condition>
  <arm_group>
    <arm_group_label>TAU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment as usual</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAU plus SALIENCE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment as usual plus computer-based intervention &quot;SALIENCE&quot;</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>SALIENCE</intervention_name>
    <description>3 computer-based training sessions with program &quot;SALIENCE&quot; per week over 3 weeks (see study description)</description>
    <arm_group_label>TAU plus SALIENCE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>TAU</intervention_name>
    <description>treatment as usual, , i.e. medically supervised detoxification treatment (i.e. medical management of withdrawal symptoms, associated physical discomfort and any co-existing disorders, etc.) as well as health education and supportive therapy sessions.</description>
    <arm_group_label>TAU</arm_group_label>
    <arm_group_label>TAU plus SALIENCE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age between 18 and 65&#xD;
&#xD;
          -  alcohol use disorder (DSM-5)&#xD;
&#xD;
          -  inpatient or part inpatient treatment&#xD;
&#xD;
          -  alcohol abstinence for at least 72 hours and maximum for three weeks&#xD;
&#xD;
          -  normal or correctable eyesight&#xD;
&#xD;
          -  Sufficient ability to communicate with the investigators, to answer questions in oral&#xD;
             and written form&#xD;
&#xD;
          -  &quot;Fully Informed Consent&quot;&#xD;
&#xD;
          -  &quot;Written Informed Consent&quot;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Withdrawal of the declaration of consent&#xD;
&#xD;
          -  severe internistic, neurological or psychiatric comorbidities&#xD;
&#xD;
          -  severe withdrawal symptoms (CIWA-R &gt; 7)&#xD;
&#xD;
          -  alcohol-intoxication (&gt; 0 ‰)&#xD;
&#xD;
          -  Pharmacotherapy with psychoactive substances within the last 14 days (except&#xD;
             Clomethiazole or Benzodiazepines within the alcohol withdrawal treatment; treatment&#xD;
             with these medications has to be completed within last 3 days)&#xD;
&#xD;
          -  Axis 1 disorder according to ICD-10 and DSM 5 (except tobacco use disorder and&#xD;
             specific phobia within the last 12 months)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabine Vollstädt-Klein</last_name>
    <role>Principal Investigator</role>
    <affiliation>ZI Mannheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik für Abhängiges Verhalten, Zentralinstitut für Seelische Gesundheit</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Württemberg</state>
        <zip>68159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 23, 2018</study_first_submitted>
  <study_first_submitted_qc>December 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2018</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

